Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2009 09:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2009 Results

CHARLOTTE, N.C., Oct. 28, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release third quarter results for the period ended September 30, 2009...
October 27, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference on Wednesday, November 4, 2009

CHARLOTTE, N.C., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference at 1:00 PM on...
October 20, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Presents Novel, Metabolically Inert Autoimmune Portfolio at the 2009 ACR Annual Scientific Meeting

CHARLOTTE, N.C., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will present results from Chelsea's two clinical stage product candidates in its portfolio of...
October 01, 2009 16:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Droxidopa Phase III Results Today At 4:30 PM ET

CHARLOTTE, N.C., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will host a conference call and live webcast to discuss the previously...
October 01, 2009 07:00 ET | Source: Chelsea Therapeutics

Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in Treatment of Neurogenic Orthostatic Hypotension

Droxidopa Demonstrates Statistically Significant Improvement On 5 Clinically Meaningful Measures of Symptomatic Neurogenic Orthostatic Hypotension ...
September 24, 2009 09:08 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Preliminary Phase III Data of Droxidopa for Treatment of Symptomatic Neurogenic Orthostatic Hypotension

* Study 302 Did Not Meet Statistical Significance on Primary Endpoint * Key Secondary Endpoints Strongly Support Symptomatic Benefit * Design of Second Study May Offer Significant Advantages *...
September 15, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present At BioCentury's Newsmakers in the Biotech Industry Conference

CHARLOTTE, N.C., Sept. 15, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at BioCentury's Newsmakers in the Biotech Industry Conference at...
September 09, 2009 07:25 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Achieves Target Enrollment in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension

* Top-line Data From First Pivotal Trial Anticipated Later This Month * Rolling NDA Submission to be Initiated in Q4 09 CHARLOTTE, N.C., Sept. 9, 2009 (GLOBE NEWSWIRE) -- Chelsea...
September 02, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present At the Rodman and Renshaw 11th Annual Healthcare Conference On Wednesday, September 9, 2009

CHARLOTTE, N.C., Sept. 2, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Rodman & Renshaw 11th Annual Healthcare Conference at 4:05...
August 05, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Second Quarter 2009 Results

CHARLOTTE, N.C., Aug. 5, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the second quarter 2009. Chelsea's management team will host a...